We will be comparing the differences between argenx SE (NASDAQ:ARGX) and Cue Biopharma Inc. (NASDAQ:CUE) as far as risk, institutional ownership, analyst recommendations, profitability, dividends, earnings and valuation are concerned. The two businesses are rivals in the Biotechnology industry.

Earnings & Valuation

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
argenx SE	N/A	0.00	N/A	-1.73	0.00
Cue Biopharma Inc.	1.14M	159.33	38.98M	-1.99	0.00

Table 1 highlights argenx SE and Cue Biopharma Inc.’s gross revenue, earnings per share and valuation.

Profitability

Table 2 shows us argenx SE and Cue Biopharma Inc.’s return on equity, net margins and return on assets.

	Net Margins	Return on Equity	Return on Assets
argenx SE	0.00%	0%	0%
Cue Biopharma Inc.	-3,419.30%	-67.9%	-62.3%

Analyst Ratings

argenx SE and Cue Biopharma Inc. Recommendations and Ratings are available on the next table.

	Sell Ratings	Hold Ratings	Buy Ratings	Rating Score
argenx SE	0	0	2	3.00
Cue Biopharma Inc.	0	0	0	0.00

argenx SE’s upside potential is 18.35% at a $150.5 average price target.

Institutional and Insider Ownership

Institutional investors held 55.31% of argenx SE shares and 20.8% of Cue Biopharma Inc. shares. Competitively, 0.3% are Cue Biopharma Inc.’s share held by insiders.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
argenx SE	2.01%	24.83%	40.83%	43.87%	61.6%	37.88%
Cue Biopharma Inc.	6.07%	33.27%	29.96%	-20.35%	-54.02%	44.89%

For the past year argenx SE’s stock price has smaller growth than Cue Biopharma Inc.

Summary

argenx SE beats Cue Biopharma Inc. on 6 of the 10 factors.

argenx SE, a clinical-stage biopharmaceutical company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The company’s lead clinical stage product candidates include ARGX-113, a product in Phase 2 clinical trials for the treatment of autoimmune diseases, including myasthenia gravis and immune thrombocytopenia; and ARGX-110, which is in Phase 1/2 clinical trials for the treatment of hematological cancers, such as T-cell lymphoma, acute myeloid leukemia, and myelodysplastic syndrome. It is also developing ARGX-111 to treat solid tumors with MET amplification; ARGX-109 for the treatment of rheumatoid arthritis; ARGX-112 to treat skin inflammation; ARGX-115, a cancer immunotherapy-focused product candidate; and ARGX-116 for the treatment of dyslipidemia. The company has license and collaboration agreements with AbbVie S.Á.R.L.; Bird Rock Bio, Inc.; LEO Pharma A/S; Shire International GmbH; and Bayer AG. argenx SE was founded in 2008 and is based in Breda, the Netherlands.

Cue Biopharma, Inc., a preclinical stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat various cancers and autoimmune disorders. Its lead drug candidate comprises CUE-101, a variant form of the cytokine Interleukin-2 and a T cell antigen to target and activate T cells specific to HPV-related cancers. The company's biologics drug candidates also include CUE-100 series to improve various tumor specific T cells; and CUE-200 series to reinvigorate exhausted T cells. It also offers MOD costimulatory optimization and discovery platform and viraTope T cell epitope discovery platform to develop novel biologics for addressing new indications in oncology and autoimmune disorders. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.